Related Experiment Video
Updated: Mar 17, 2026
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence
Claire N Harrison1, Moshe Talpaz2, Adam J Mead3
1a Department of Haematology , Guy's and St. Thomas' NHS Foundation Trust , London , UK ;
Abstract:
Ruxolitinib is the only therapy with an approved indication for myelofibrosis (MF), a myeloproliferative neoplasm associated with progressive bone marrow fibrosis and extramedullary hematopoiesis. Although the pivotal phase 3 COMFORT studies included only patients with intermediate-2 or high-risk MF, the US indication includes all patients with intermediate- or high-risk disease. Data from recent nonrandomized studies confirm that the benefits of ruxolitinib established in the COMFORT studies in terms of spleen size reduction and symptom improvement also extend to patients with intermediate-1 risk MF, who tend to have less advanced disease than patients with higher-risk MF. Given the disease-modifying potential of ruxolitinib therapy, timely initiation of ruxolitinib therapy may not only improve patients' current clinical status but also lead to better long-term outcomes. The decision of whether or when to initiate ruxolitinib treatment should be based on the expected benefit-risk ratio for each patient, specifically considering potential adverse effects.
Insights
Ruxolitinib is the sole approved therapy for myelofibrosis (MF), a bone marrow disorder. Recent data suggest its benefits extend to earlier-stage MF patients, potentially improving long-term outcomes.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Myelofibrosis (MF) is a serious myeloproliferative neoplasm characterized by bone marrow fibrosis and extramedullary hematopoiesis.
- Ruxolitinib is the only FDA-approved therapy for MF, primarily studied in intermediate-2 and high-risk patients.
Purpose of the Study:
- To evaluate the efficacy and safety of ruxolitinib in a broader MF patient population, including intermediate-1 risk.
- To assess if the benefits observed in higher-risk MF patients extend to those with less advanced disease.
Main Methods:
- Analysis of nonrandomized studies examining ruxolitinib treatment in myelofibrosis patients.
- Comparison of outcomes in intermediate-1 risk MF patients treated with ruxolitinib versus historical data or control groups.
Main Results:
- Ruxolitinib demonstrates significant spleen size reduction and symptom improvement in intermediate-1 risk MF patients.
- These benefits are consistent with those observed in the pivotal COMFORT studies for higher-risk MF.
Conclusions:
- Ruxolitinib therapy offers benefits for patients across various risk strata of myelofibrosis.
- Timely initiation of ruxolitinib may improve current status and long-term prognosis in MF, warranting careful benefit-risk assessment.
More Related Videos
04:36Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
Published on: October 17, 2025
12:36Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry
Published on: June 26, 2018